269071-77-4Relevant academic research and scientific papers
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists
Buck, Ildiko M.,Black, James W.,Cooke, Tracey,Dunstone, David J.,Gaffen, John D.,Griffin, Eric P.,Harper, Elaine A.,Hull, Robert A. D.,Kalindjian, S. Barret,Lilley, Elliot J.,Linney, Ian D.,Low, Caroline M. R.,McDonald, Iain M.,Pether, Michael J.,Roberts, Sonia P.,Shankley, Nigel P.,Shaxted, Mark E.,Steel, Katherine I. M.,Sykes, David A.,Tozer, Matthew J.,Watt, Gillian F.,Walker, Martin K.,Wright, Laurence,Wright, Paul T.
, p. 6803 - 6812 (2007/10/03)
The systematic optimization of the structure of a novel 2,4,5-trisubstituted imidazole-based cholecystokinin-2 (CCK2) receptor antagonist afforded analogues with nanomolar receptor affinity. These compounds were now comparable in their potency
Scaffold hopping with molecular field points: Identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists
Low, Caroline M. R.,Buck, Ildiko M.,Cooke, Tracey,Cushnir, Julia R.,Kalindjian, S. Barret,Kotecha, Atul,Pether, Michael J.,Shankley, Nigel P.,Vinter,Wright, Laurence
, p. 6790 - 6802 (2007/10/03)
A new molecular modeling approach has been used to derive a pharmacophore of the potent and selective cholecystokinin-2 (CCK2) receptor antagonist 5 (JB93182), based on features shared with two related series. The technique uses "field points"
